Conference Coverage
Latest News
Dec 12, 2025 | News
NeurologyLive® Friday 5 — December 12, 2025
Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine
Dec 12, 2025
FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis
Dec 12, 2025
Episode 156: Building Better Mood and Behavior Care for Parkinson Disease
Dec 12, 2025
FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS
Dec 11, 2025
Advertisement
Shorts
Media-Driven Misconceptions of Narcolepsy
a day ago
by
Julie Flygare, JD(+1 more)
0:30
Barriers to Early Diagnosis and Access to Care in MS
22 days ago
by
Ethel Ciampi, MD, MSc(+1 more)
1:30
Collaboration Within the ALS Community
a month ago
by
Jinsy A. Andrews, MD, MSc(+1 more)
1:30
Safety Considerations for Kygevvi in Tk2d
a month ago
by
Fabian Somers, PhD(+1 more)
1:30
Data Backing First Treatment for Tk2d
a month ago
by
Fabian Somers, PhD(+1 more)
1:30
Training the Next Neuromuscular Specialists
a month ago
by
John Norbury, MD(+1 more)
1:15
Evolving Landscape of Myasthenia Gravis Treatment
a month ago
by
Leila Darki, MD(+1 more)
1:05
Aerobic Exercise and Promoting Remyelination in MS
2 months ago
by
Lindsey Wooliscroft, MD, MS(+1 more)
1:12
MDS 2025: Learning From Progress in Other Disease States
2 months ago
by
Lorraine Kalia, MD, PhD(+1 more)
1:16
MDS 2025: Biologically Defining Parkinson Disease
2 months ago
by
Tanya Simuni, MD, FAAN(+1 more)
Coverage of AANEM 2025
Get direct access to interviews with experts, straight from the conference floor in San Francisco, as well as the latest data and clinical news updates.
Mind Moments Podcast
Mind Moments® is a biweekly podcast from NeurologyLive that brings you exclusive interviews with expert neurologists and clinicians.
DAMM Good Sleep
Check out DAMM Good Sleep × NeurologyLive for neurology-focused sleep content to allow any neurology stakeholder to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it should be.
NeuroVoices
NeuroVoices is NeurologyLive's series of in-depth, exclusive Q&A conversations with a variety of experts in the care and management of patients with neurologic diseases about topics in clinical care and therapeutic development.
Gold Standard Centers
Gold Standard Centers is our deep dive feature series on examples of institutional success in neurologic medicine, highlighting the centers that are leading the way in care.
Videos
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.
Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.
New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.
Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.
Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.
New findings reveal bexicaserin significantly reduces seizure frequency in patients with developmental and epileptic encephalopathies, supporting its advancement to phase 3 trials.
A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.
A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.
The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.
TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.
Advertisement
The positive interim findings research represents the first clinical data for ETX101, an investigational cell-type-selective gene therapy, and the first potential one-time disease-modifying treatment for Dravet syndrome.
PERC Analysis Highlights Factors Influencing Candidacy for Pediatric Drug-Resistant Epilepsy Surgery
A new study presented at AES 2025 examined factors linked to declining surgery for pediatric drug-resistant epilepsy and highlighted variability in candidate selection across centers.
Sharon Hesterlee, PhD, President and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.
A new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.
Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.
Advertisement
Advertisement
